Drugs / 5-fluoro-2-deoxycytidine
5-fluoro-2-deoxycytidine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01534598 | Mar 2012 → Oct 2019 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01041443 | Dec 2009 → Oct 2013 | acute myeloid leukemia, myelodysplastic syndrome | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00359606 | Apr 1999 → Jun 2012 | neoplasm | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00978250 | Aug 2009 → Apr 2019 | breast neoplasm, head and neck neoplasm, lung neoplasm, urinary bladder neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5-fluoro-2-deoxycytidine | “FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are experimental cancer treatment drugs.” NCT01534598 ↗ |
| Known as | FdCyd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01534598 ↗ |
| Known as | NSC48006 | “5-Fluoro-2'-deoxycytidine (FdCyd; NSC48006), a fluoropyrimidine nucleoside inhibitor of DNA methylation” PMID 26321472 ↗ Sep 2015 |
| Action | Inhibit | “5-Fluoro-2'-deoxycytidine (FdCyd; NSC48006), a fluoropyrimidine nucleoside inhibitor of DNA methylation” PMID 26321472 ↗ Sep 2015 |
| Modality | Small molecule | “5-Fluoro-2'-deoxycytidine (FdCyd; NSC48006), a fluoropyrimidine nucleoside inhibitor of DNA methylation” PMID 26321472 ↗ Sep 2015 |
| Route | Intravenous | “Given PO and IV” NCT00359606 ↗ |
| Route | Oral | “Given PO and IV” NCT00359606 ↗ |